# Dasatinib in Combination With Revlimid (and Dexamethasone)

> **NCT00560391** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 35 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Dasatinib, 70 mg + Lenalidomide, 15 mg + Dexamethasone, 40 mg
- **DRUG:** Dasatinib, 70 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg
- **DRUG:** Dasatinib, 100 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg
- **DRUG:** Dasatinib, 100 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg
- **DRUG:** Dasatinib, 140 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg

## Key facts

- **NCT ID:** NCT00560391
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2011-10
- **Final completion:** 2012-11
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2016-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00560391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00560391, "Dasatinib in Combination With Revlimid (and Dexamethasone)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00560391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*